Figure 4.

Cytotoxicity of different liposomal combinations of doxorubicin (DXR) and C6-ceramide against ovarian cancer cell lines. The indicated ovarian cancer cell lines were incubated for 1, 4 or 8 h with F3 peptide-targeted liposomal DXR ([F3]L-D) or DXR:C6-ceramide combination at a molar ratio of 1:1 or 1:2 ([F3]L-DC₆11 and [F3]L-DC₆12, respectively), at DXR serially diluted concentrations. The experiment was further prolonged for a total of 96 (TOV-112D), 120 (SKOV-3) or 144 h (OVCAR-3) after which cell viability was assessed. Additional controls included liposomes either functionalized by a non-specific peptide ([NS]L-D, [NS]L-DC₆11 and [NS]L-DC₆12) or non-targeted (L-D, L-DC₆11 and L-DC₆12), incubated under the same experimental conditions. The mean DXR concentrations enabling 50% (IC₅₀) or 90% (IC₉₀) cytotoxicity are presented, where the circle size and color reflected the mean DXR concentration value (µM, n = 3): the smaller the size and the greener the color, the higher the cytotoxic potency.